Long-Lasting Activation of the Transcription Factor CREB in Sensory Neurons by Interleukin-1β During Antigen-Induced Arthritis in Rats: A Mechanism of Persistent Arthritis Pain?

Arthritis Rheumatol. 2016 Feb;68(2):532-41. doi: 10.1002/art.39445.

Abstract

Objective: In spite of successful treatment of immune-mediated arthritis, many patients still experience pain. We undertook this study to investigate whether antigen-induced arthritis (AIA) in rats triggers neuronal changes in sensory neurons that outlast the inflammatory process.

Methods: We induced unilateral AIA in the knee joint and assessed in sensory neurons the expression of CREB, a transcription factor that regulates genes involved in neuronal plasticity. We tested whether neutralization of the effects of tumor necrosis factor (TNF) by etanercept or infliximab or neutralization of the effects of interleukin-1β (IL-1β) by anakinra influences the up-regulation of phospho-CREB, and we studied the up-regulation of phospho-CREB by IL-1β and TNF in cultured dorsal root ganglion (DRG) neurons.

Results: Unilateral AIA caused bilateral up-regulation of phospho-CREB in lumbar DRG neurons. While inflammation and pain subsided within 21 days, the up-regulation of phospho-CREB still persisted on day 42. At this time point mechanical hyperalgesia at the knee reappeared in the absence of swelling. TNF neutralization during AIA significantly reduced pain-related behavior but did not prevent phospho-CREB up-regulation. In contrast, anakinra, which only reduced thermal hyperalgesia, prevented phospho-CREB up-regulation, suggesting a role of IL-1β in this process. In cultured DRG neurons the application of IL-1β significantly enhanced phospho-CREB.

Conclusion: Immune-mediated arthritis causes neuroplastic changes in sensory neurons that outlast the inflammatory phase. Such changes may facilitate the persistence or recurrence of pain after remission of arthritis. IL-1β is an important trigger in this process, although its neutralization barely reduced mechanical hyperalgesia during inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antirheumatic Agents / pharmacology
  • Arthritis, Experimental / genetics*
  • Arthritis, Experimental / metabolism
  • Cells, Cultured
  • Cyclic AMP Response Element-Binding Protein / drug effects
  • Cyclic AMP Response Element-Binding Protein / genetics*
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Etanercept / pharmacology
  • Female
  • Ganglia, Spinal / cytology
  • Gene Expression Regulation
  • Hyperalgesia / genetics*
  • Hyperalgesia / metabolism
  • Infliximab / pharmacology
  • Interleukin 1 Receptor Antagonist Protein / pharmacology
  • Interleukin-1beta / pharmacology
  • Neuronal Plasticity
  • Pain / genetics
  • Pain / metabolism
  • Rats
  • Rats, Inbred Lew
  • Sensory Receptor Cells / drug effects
  • Sensory Receptor Cells / metabolism*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / metabolism
  • Up-Regulation / drug effects

Substances

  • Antirheumatic Agents
  • Creb1 protein, rat
  • Cyclic AMP Response Element-Binding Protein
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept